SEC Tracker
Get the app

Bristol Myers Squibb BMY

Bristol Myers Squibb reports stock changes

Michael R. McMullen, insider filing for BMY

Form
4
Filed
Importance
Routine
  1. Michael R. McMullen, director
  2. Sep 30, 2026 transaction date
  3. 560.897 deferred share units acquired
  4. Includes deferred compensation and dividends

Written from the Form 4 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Bristol Myers Squibb files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Gilead Sciences GILD public float $103.2B, Jun 30, 2025
  2. Vertex Pharmaceuticals VRTX public float $113.4B, Jun 30, 2025
  3. Zoetis ZTS public float $69.2B, Jun 30, 2025
  4. Pfizer PFE public float $138.0B, Jun 29, 2025
  5. Amgen AMGN public float $150.1B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.